124 related articles for article (PubMed ID: 19199267)
41. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
[TBL] [Abstract][Full Text] [Related]
42. [Analysis for clinicopathological features, therapy and prognosis of 30 elderly patients with non-Hodgkin's lymphoma].
Wang HT; Yang B; Cai LL; Ran HH; Zhang WY; Zhu HL; Yang Y; Li SX; Fan H; Chi XH; Yu RL; Zhang F; Li BL; Lin J; Zhai B; Yao SQ; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1464-70. PubMed ID: 24370030
[TBL] [Abstract][Full Text] [Related]
43. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
44. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
45. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
Kim HD; Cho H; Jeong H; Bang K; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Oh SY; Suh C
Br J Haematol; 2021 Apr; 193(2):307-315. PubMed ID: 33216979
[TBL] [Abstract][Full Text] [Related]
46. Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index.
Aydin F; Ulusoy S; Ovali E
J Chemother; 1997 Dec; 9(6):446-51. PubMed ID: 9491847
[TBL] [Abstract][Full Text] [Related]
47. [Clinical Characteristics of 219 Patients with Primary Gastrointestinal Non-Hodgkin's Lymphoma].
Li YY; Hu DZ; Wang YF; Zhao ZG; Cao Z; Zhang YZ; Zhang HL; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):849-854. PubMed ID: 32552946
[TBL] [Abstract][Full Text] [Related]
48. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
Nicolaides C; Fountzilas G; Zoumbos N; Skarlos D; Kosmidis P; Pectasides D; Karabelis A; Giannakakis T; Symeonidis A; Papadopoulos A; Antoniou F; Pavlidis N
Oncology; 1998; 55(5):405-15. PubMed ID: 9732217
[TBL] [Abstract][Full Text] [Related]
49. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.
Bien E; Rapala M; Krawczyk M; Balcerska A
J Cancer Res Clin Oncol; 2010 Feb; 136(2):293-305. PubMed ID: 19693535
[TBL] [Abstract][Full Text] [Related]
50. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
[TBL] [Abstract][Full Text] [Related]
52. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma.
Demir I; Akan OY; Bilgir F; Yilmaz I; Bozkaya G; Bilgir O
Ir J Med Sci; 2024 Jun; 193(3):1201-1207. PubMed ID: 38270775
[TBL] [Abstract][Full Text] [Related]
53. Assessment of prognostic factors in follicular lymphoma patients.
Kondo E; Ogura M; Kagami Y; Taji H; Miura K; Takeuchi T; Maeda S; Asakura S; Suzuki R; Nakamura S; Morishima Y
Int J Hematol; 2001 Apr; 73(3):363-8. PubMed ID: 11345204
[TBL] [Abstract][Full Text] [Related]
54. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma.
Mok TS; Steinberg J; Chan AT; Yeo WM; Hui P; Leung TW; Johnson P
Cancer; 1998 Jun; 82(12):2439-48. PubMed ID: 9635538
[TBL] [Abstract][Full Text] [Related]
55. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience.
Nachbaur D; Oberaigner W; Fritsch E; Nussbaumer W; Gastl G
Eur J Haematol; 2001 Jan; 66(1):43-9. PubMed ID: 11168507
[TBL] [Abstract][Full Text] [Related]
56. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies.
Bouafia F; Drai J; Bienvenu J; Thieblemont C; Espinouse D; Salles G; Coiffier B
Bull Cancer; 2004; 91(7-8):E229-40. PubMed ID: 15381461
[TBL] [Abstract][Full Text] [Related]
57. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma.
Yoh KA; Lee HS; Park LC; Lee EM; Shin SH; Park DJ; Ye BJ; Kim YS
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):43-9. PubMed ID: 24200518
[TBL] [Abstract][Full Text] [Related]
58. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer].
Bień E; Balcerska A
Med Wieku Rozwoj; 2004; 8(4 Pt 2):1081-9. PubMed ID: 15951603
[TBL] [Abstract][Full Text] [Related]
59. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
[TBL] [Abstract][Full Text] [Related]
60. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers.
Christiansen I; Gidlof C; Kälkner K M; Hagberg H; Bennmarker H; Tötterman T
Br J Haematol; 1996 Mar; 92(3):639-46. PubMed ID: 8616029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
